Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 3/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230909 | 0.89 | CASP1 (0.52) | PPARAPPARGCTSLCTSBCTSS | |
| SCHEMBL4973400 | 0.87 | CASP1 (0.62) | PPARAPPARGCTSLCTSBCTSS | |
| SCHEMBL6487973 | 0.87 | CASP1 (0.62) | PPARAPPARGCTSLCTSBCTSS | |
| SCHEMBL1541597 | 0.87 | CASP1 (0.62) | PPARAPPARGCTSLCTSBCTSS | |
| SCHEMBL7810068 | 0.86 | CASP1 (0.61) | PPARAPPARGCTSLCTSBCTSS | |
| SCHEMBL7810073 | 0.86 | CASP1 (0.61) | PPARAPPARGCTSLCTSBCTSS | |
| SCHEMBL7309215 | 0.86 | PPARA (0.55) | PPARAPPARGCTSSCASP1CA2 | |
| SCHEMBL7309224 | 0.86 | PPARA (0.55) | PPARAPPARGCTSSCASP1CA2 | |
| SCHEMBL6654073 | 0.83 | CYP3A4 (0.54) | PPARAPPARGCTSLCTSBCTSS | |
| SCHEMBL18623602 | 0.81 | CTSB (0.72) | CTSLCTSBCTSSCASP1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1340744-B1 | Hiv protease inhibitors | AGOURON PHARMA (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-0889036-B1 | HIV protease inhibitors | AGOURON PHARMA (US) | 2004-12-29 | — | — | EP | disclosed |
| US-6693199-B2 | DEPROTECTING CARBAMATE GROUP AND AMIDATING IN PRESENCE OF SUCH AS HYDROXYBENZOTRIAZOLE HYDRATE PROMOTER | AGOURON PHARMACEUTICALS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030216569-A1 | Method of making HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1340744-A2 | Hiv protease inhibitors | Agouron Pharmaceuticals, Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6525215-B2 | As antiviral agents suitable for therapy of patients or hosts infected with the HIV virus, which is known to cause AIDS | AGOURON PHARMACEUTICALS, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-0722439-B1 | HIV PROTEASE INHIBITORS | AGOURON PHARMA (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20020077338-A1 | HIV protease inhibitors | DRESSMAN BRUCE A (US) | 2002-06-20 | — | — | US | disclosed |
| US-6271235-B1 | VIRICIDE | AGOURON PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | disclosed |
| US-6162812-A | Pharmaceutical compositions containing HIV protease inhibitors and methods of their use | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-19 | — | — | US | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5475136-A | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1995-12-12 | — | — | US | disclosed |
| WO-1995032185-A1 | N-(3-AMINO-2-HYDROXYBUTYL)SULPHONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| US-5461154-A | HIV protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1995021164-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1995-08-10 | — | — | WO | disclosed |
| US-5434265-A | Inhibitors of HIV protease | ELI LILLY AND COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0609625-A1 | Inhibitors of HIV protease useful for the treatment of AIDS | ELI LILLY AND COMPANY (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0604185-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
| EP-0604183-A1 | Inhibitors of HIV protease useful for the treatment of aids | ELI LILLY AND COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077338-A1 | HIV protease inhibitors | PREP, PRSS1, SERPINB1 | PPARA 4380/4885PPARG 4600/4885CTSL 29/4885 |
| US-20030216569-A1 | Method of making HIV protease inhibitors | SERPINB1, PRSS1, PREP | PPARA 4822/4885PPARG 4837/4885CTSL 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.